Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-NMI (1-307) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.02% Sodium Azide, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:2000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
NMI |
Gene ID: |
9111 |
Uniprot ID: |
NMI_HUMAN |
Immunogen Region: |
1-307 |
Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 1-307 of human NMI (NP_004679.2). |
Immunogen Sequence: |
MEADKDDTQQILKEHSPDEF IKDEQNKGLIDEITKKNIQL KKEIQKLETELQEATKEFQI KEDIPETKMKFLSVETPEND SQLSNISCSFQVSSKVPYEI QKGQALITFEKEEVAQNVVS MSKHHVQIKDVNLEVTAKPV PLNSGVRFQVYVEVSKMKIN VTEIPDTLREDQMRDKLELS FSKSRNGGGEVDRVDYDRQS GSAVITFVEIGVADKILKKK EYPLYINQTCHRVTVSPYT |
Tissue Specificity | Expressed in adult spleen, liver, and kidney. Expressed in fetal thymus, liver, placenta, spleen, lung, and kidney but not brain. Expressed in macrophages. |
Post Translational Modifications | Ubiquitinated. 'Lys-63'-linked ubiquitination by TRIM21 promotes interaction with IFI35 and inhibits virus-triggered type I IFN-beta production. |
Function | Acts as a signaling pathway regulator involved in innate immune system response. In response to interleukin 2/IL2 and interferon IFN-gamma/IFNG, interacts with signal transducer and activator of transcription/STAT which activate the transcription of downstream genes involved in a multitude of signals for development and homeostasis. Enhances the recruitment of CBP/p300 coactivators to STAT1 and STAT5, resulting in increased STAT1- and STAT5-dependent transcription. In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator IFI35 to regulate immune response.the complex formation prevents proteasome-mediated degradation of IFI35. In complex with IFI35, inhibits virus-triggered type I IFN-beta production when ubiquitinated by ubiquitin-protein ligase TRIM21. In complex with IFI35, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries. Negatively regulates virus-triggered type I interferon/IFN production by inducing proteosome-dependent degradation of IRF7, a transcriptional regulator of type I IFN, thereby interfering with cellular antiviral responses. Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation, when actively released by macrophage to the extracellular space during cell injury or pathogen invasion. Macrophage-secreted NMI activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 binding and activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines. |
Protein Name | N-Myc-InteractorNmiN-Myc And Stat Interactor |
Database Links | Reactome: R-HSA-9692916 |
Cellular Localisation | CytoplasmNucleusSecretedCytoplasmic Nmi Localizes In Punctate Granular StructuresNuclear Localization Increased Following Ifn-Alpha TreatmentExtracelullar Following Secretion By Macrophage |
Alternative Antibody Names | Anti-N-Myc-Interactor antibodyAnti-Nmi antibodyAnti-N-Myc And Stat Interactor antibodyAnti-NMI antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance